novo glp 1 drugs Details of failed studies cast pall on Nordisk's GLP-1 as Alzheimer's treatment Novo Nordisk Expands GLP-1 Access

While the inflammation-reducing and fibrosis-attenuating effects of glucagon agonism are less well-characterized, the reductions in hepatic inflammation parameters and fibrosis observed in preclinical models likely reflect secondary effects consequent to improved steatosis, rather than direct anti-inflammatory actions [21]

Bariatric surgery typically leads to more rapid and substantial weight loss compared to medication

GLP-1 medications address multiple parts of this equation simultaneously

Red flag symptoms requiring urgent assessment: Severe, persistent vomiting Inability to tolerate oral intake for more than 24 hours, suggesting possible gastroparesis or other complications Signs of dehydration Decreased urine output, dizziness, dry mucous membranes, or tachycardia Severe abdominal pain Particularly if acute, localized, or associated with fever, which may indicate pancreatitis or other acute abdominal pathology Right upper quadrant pain, fever, or jaundice Suggesting possible gallbladder disease Severe abdominal distension with inability to pass stool or gas Potential bowel obstruction or ileus Hematemesis or melena Suggesting gastrointestinal bleeding Progressive dysphagia Difficulty swallowing that worsens over time Situations requiring routine consultation: Patients should contact their healthcare provider for non-urgent evaluation when experiencing persistent nausea or vomiting lasting beyond 2-3 weeks at a stable dose, as this may indicate inadequate adaptation or the need for dose adjustment

At Rs 1,0002,500 a month, it's cheaper than a gym membership